**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 63510

**Manuscript Type:** SYSTEMATIC REVIEWS

**Laboratory hematologic features of COVID-19 associated liver injury: A systematic review**

Frater JL *et al*. Laboratory hematologic features of COVID-19-associated liver injury

John L Frater, Tianjiao Wang, Yi-Shan Lee

**John L Frater, Tianjiao Wang, Yi-Shan Lee,** Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, United States

**Author contributions:** Frater JL designed the research study, performed the research, analyzed the data, and wrote the manuscript; Wang T and Lee YS analyzed the data; All authors have read and approved the final manuscript.

**Corresponding author: John L Frater, MD, Associate Professor,** Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8118, 3rd Floor, Rm 3421, Institute of Health Bldg, St. Louis, MO 63110, United States. jfrater@wustl.edu

**Received:** January 28, 2021

**Revised:** March 31, 2021

**Accepted:** April 23, 2021

**Published online:** April 28, 2021

**Abstract**

BACKGROUND

Liver injury is a common complication of infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The utility of laboratory hematology data in the diagnosis and risk stratification of patients with coronavirus disease 2019 (COVID-19) has not been comprehensively examined.

AIM

To address the following. (1) Are the abnormalities in hematologic parameters seen in the general population of patients with COVID-19 also seen in those patients with associated liver injury? (2) Is liver injury in COVID-19 a sign of severe disease and does liver injury correlate with hematologic markers of severe disease? (3) What is the quality of this evidence?

METHODS

To address these questions, a comprehensive systematic review was performed. We searched the peer reviewed medical literature using MEDLINE (PubMed interface), Web of Science, and Embase for cohort studies that specifically addressed liver injury and COVID-19 without limitation of date of publication or language. A quality assessment of the studies was performed using the Newcastle-Ottawa Scale.

RESULTS

Thirty-two articles were suitable for inclusion in our systematic review. These included 22 articles with a cohort of COVID-19 patients with liver injury, 5 comparing non-severe *vs* severe COVID-19 populations in which liver injury was addressed, and 5 other cohort studies with a focus on liver injury. White blood cell count, absolute neutrophil count, absolute lymphocyte count (ALC), and hemoglobin were the parameters most helpful in distinguishing COVID-19 with liver injury from COVID-19 without liver injury. ALC and d-dimer were identified as being potentially useful in distinguishing non-severe from severe COVID-19. Liver injury was more frequently seen in cohorts with severe disease. Most studies were of high quality (24/48, 86%) with 4/28 (14%)of moderate quality and 0 of low quality.

CONCLUSION

Our study supports the use of select hematologic parameters in diagnosis and risk stratification of liver injury in COVID-19 patients. Although of overall high quality, the current medical literature is limited by the small number of studies with high statistical power and the variable definition of COVID-19 liver injury in the literature.

**Key Words:** COVID-19; SARS-CoV-2; Laboratory hematology; Systematic review; Coagulation; Liver injury

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Frater JL, Wang T, Lee YS. Laboratory hematologic features of COVID-19 associated liver injury: A systematic review. *World J Meta-Anal* 2021; 9(2): 193-207

URL: https://www.wjgnet.com/2308-3840/full/v9/i2/193.htm

DOI: https://dx.doi.org/10.13105/wjma.v9.i2.193

**Core Tip:** The use of laboratory hematology data as biomarkers of disease has not been examined for coronavirus disease 2019 (COVID-19) patients with liver injury, and the clinical significance of liver injury in COVID-19 is unclear. By means of a systematic review we showed that blood cell count, absolute neutrophil count, absolute lymphocyte count (ALC), and hemoglobin are of potential use in identifying liver failure in COVID-19. ALC and d-dimer have potential utility in distinguishing severe from non-severe disease in patients with liver injury. Our findings provide a rationale for further studies with sufficiently large numbers of patients and rigorous definition of liver injury to validate these findings.

**INTRODUCTION**

***Rationale***

The coronavirus disease 2019 (COVID-19) pandemic, caused by infection by the beta coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been the subject of a vast number of studies in the medical literature; a January 16, 2021 search of the MEDLINE database (PubMed interface) for “COVID-19” identified 92967 results. A recent scoping review of the laboratory hematology literature identified > 400 studies, of which a high fraction were related to the roles of automated hematology, coagulation, and flow cytometry for diagnosis, prognosis, and risk stratification in COVID-19[1]. As a result of this work, several abnormalities of complete blood count (CBC) and coagulation testing have been identified as biomarkers of adverse risk in infected patients. These includeleukocytosis[2], lymphopenia[2-4], thrombocytopenia[2,5], neutrophilia[2,3,6-9], prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT)[2], and elevated d-dimer[1,2]. It is unclear whether this information can be applied to specific subpopulations of patients with COVID-19 disease, such as those with liver injury[10].

Liver injury in COVID-19 has been defined as “any liver damage occurring during disease progression and treatment of SARS-CoV-2 infection”[11]. The classification of liver injury in COVID-19 is not systematized due to a lack of international consensus[12-15]. Elevated biochemical liver enzymes including aspartate transaminase (AST), alanine transaminase (ALT), and bilirubin (BILI) are a common finding in COVID-19 infection[2,4,6,16,17] and have been reported in approximately 50% of all COVID-19 patients and approximately 75% of hospitalized patients at admission[18-23]. COVID-19-related liver injury has been variously defined by increased levels of AST, AST, gamma-glutamyltransferase (GGT), lactate dehydrogenase, alkaline phosphatase (ALP), or total bilirubin (T-BIL) above the upper limit of normal (ULN)[13,19,21,24-28]. Whether the elevation of liver enzymes in COVID-19 patients reflects liver injury in all cases is controversial[29], although a study by Bloom *et al*[30] concluded that elevated liver enzymes in hospitalized patients appeared to be related to true liver injury. The mechanism of liver injury is unclear and may be due to the direct effects of the virus, drug effect, the impact of systemic inflammation, microthrombosis, or some combination of factors[21,31-37]. The extent to which COVID-19-associated liver injury contributes to morbidity and mortality is controversial, although the current literature suggests that higher levels of liver enzymes correlate with more severe liver injury[16,38-42].

***Objectives***

The purpose of this study was to assess the medical literature to answer the following questions. (1) To what extent are previously reported hematologic abnormalities seen in patients with COVID-19-associated liver injury? (2) Based on the combination of outcome data and hematologic findings, is liver injury in COVID-19 a sign of severe disease? Does liver injury correlate with markers of severe disease? (3) What is the quality of this evidence? These questions are significant, since CBC and coagulation testing are among the most commonly ordered clinical laboratory tests, provide rapid results, and can be performed in virtually any setting, including resource-limited environments in which SARS-CoV-2 testing is unavailable. This is a systematic review that uses specific evidence-based criteria based on “explicit, pre-specified, and reproducible methods”[43] to demonstrate where knowledge is lacking and provide guidance for future research[44].

**MATERIALS AND METHODS**

***Format***

This study was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist.

***Information sources and search strategy***

We conducted an electronic search of Medline (PubMed interface), Embase, and Web of Science using the keywords “COVID-19” and synonyms (“SARS-CoV-2,” “2019 novel coronavirus,” “2019-nCoV,” “Wuhan coronavirus,” “novel coronavirus,” “Wuhan seafood market pneumonia virus,” “Wuhan virus”) AND “liver injury.” The search was performed performed on January 13, 2021 without date limitations. This protocol has not been registered. Individual authors were not contacted.

***Eligibility criteria***

We included the COVID-19 literature related to liver injury indexed by January 13, 2021. There was no restriction of article type in the search; restrictions of article type were applied during the screening process to avoid inadvertently missing relevant articles.

***Data collection process***

Titles and abstracts of all articles were screened. Following initial screening, the full text of all studies considered for potential inclusion in the analyses were reviewed for suitability. For articles published in Chinese, the full text was evaluated by a member of the research team fluent in that language (Lee YS). Then reviews, meta-analyses, editorials and other opinion pieces, and articles not focused on the study topic were removed. The full text of the articles was reviewed, resulting inanother group of papers beingeliminated. This resulted in a final group of articles remaining for the qualitative analyses, which included: Studies with a COVID-19 (+) cohort with liver injury provided as a distinct cohort; studies that compared patients with severe *vs* non-severe COVID-19 disease, in which information about liver injury in these groups was provided; and papers with other study designs that included information regarding liver injury in COVID-19 disease. The content of the included studies was critically appraised by the authors, who are experts in the field of pathology/laboratory hematology (Lee YS, Frater JL) or clinical science (Wang T).

***Synthesis of results***

Extracted data and descriptive statistics were entered and performed using Excel (Microsoft, Redmond, WA, United States). For studies in which a COVID-19 (+) cohort with liver injury provided as a distinct group, the following data were extracted: Authors; date of publication; country where study was performed; number of patients in COVID-19 (+) cohort with liver injury; percentage of male patients in COVID-19, (+) cohort with liver injury; setting in which the study was performed; criteria for liver injury used by the study; presence of, and criteria for inclusion in the control group; hematologic parameters evaluated in the study; and results of studies of statistical significance of each hematologic parameter. For studies that compared patients with severe *vs* non-severe COVID-19 disease, the following information was extracted: Authors, date of publication, country where study was performed, number of patients in the COVID-19 (+) cohort with liver injury, setting in which the study was performed, criteria used by the study to categorize patients as having severe disease, criteria for liver injury used by the study, hematologic parameters evaluated in the study, and summary of the main findings as they pertain to the study topic. For papers with other study designs, the following information was extracted: Authors, date of publication, country where study was performed, setting in which the study was performed, hematologic parameters evaluated in the study, description of study design, and summary of the main findings as they pertain to the study topic.

***Additional analyses (quality assessment)***

Two authors (Wang T and Frater JL) assessed the study quality of the cohort studies using the Newcastle-Ottawa Scale (NOS)[45]. We designated the quality of each study as high (7-9 points), moderate (4-6 points), or low (0-3 points). In situations where the reviewers disagreed on a rating, a third reviewer (Lee YS) adjudicated and provided consensus.

**RESULTS**

***Study selection***

Through a search of the databases, we identified a total of 967 potential articles. Following the removal duplicate articles, we screened the titles and abstracts of the remaining articles to further identify potentially relevant articles. After thorough assessment of all full-text articles, 32 studies met the established inclusion criteria and were included in this systematic review (Figure 1).

***Study characteristics***

A total of 22 studies had a COVID-19 (+) cohort with liver injury provided as a distinct group(Table 1)[26,46-66].

All studies were retrospective and included nine studies from China, five studies from the United States, two studies from Japan, two studies from Iran, and one study each from Germany, Portugal, France, and Italy. The median number of patients in the liver injury cohort of each study varied from 2 to 1784 (median 73.5 patients). A male predominance was identified in all but four studies. In 19 studies, the COVID-19(+) with liver injury group was presented as a single cohort. Inclusion criteria for the study groups were variable. In 15 studies, all patients with a combination of AST, ALT, BILI, and GGT exceeding the ULN were categorized in the liver injury group. In one study, the liver injury group was limited to patients with ALT ≥ 3 times the ULN[53]. In the remaining studies, the COVID-19(+) with liver injury groups were stratified into two[48,55] or three groups[60] based on serum liver enzyme levels. In one study[54], a study reporting the results of liver biopsy in two COVID-19 patients with liver involvement and no evidence of pulmonary disease, inclusion in the study was based on the results of the liver biopsies. In another study[56], an autopsy-based report of 11 patients, inclusion was based on positive RT-PCR testing of liver tissue for SARS-Cov-2. The average age of the study group ranged from 41-years-old to 70-years-old. In all but three studies a male predominance was seen in the liver injury group. Most studies drew their study group from hospitalized inpatients, one study was conducted with critical care patients, and two studies were conducted with non-critical care inpatients.

Eighteen studies (4973 patients) in this group contained statistical data that allowed comparative analyses of the following hematologic parameters: White blood cell count (WBC), absolute neutrophil count (ANC), absolute lymphocyte count (ALC), hemoglobin (HGB), platelet (PLT) count, d-dimer (DDIM), PT, PTT, and international normalized ratio (INR) (Table 2).

Although a direct comparison of the studies is limited by several factors such as heterogenous inclusion criteria and variable sample sizes, the majority of studies in which the inclusion criteria for liver injury were liver enzyme levels > ULN have demonstrated statistically significant differences in WBC, ANC, and ALC between non-liver injury *vs* liver injury groups. Although smaller numbers of studies have addressed patients with higher elevations of liver enzymes, there were still statistically significant differences in WBCs between non-liver injury *vs* liver injury groups. Limiting the analysis to studies with > 100 patients in the high liver function test (LFT) cohort (*n* = 10 studies, 4564 patients), statistically significant differences in WBC, ANC, ALC, and HGB were identified between non-liver injury *vs* liver injury groups in the majority of studies. These differences appear most pronounced for WBCs and HGB, in which all studies demonstrated statistical significance; and ANC, in which 5/6 studies demonstrated statistical significance.

Five additional studies (425 patients), all retrospective, compared COVID-19 patients with severe *vs* non-severe disease and contained information about liver injury[67-71]. The major features of these studies are summarized in Table 3and provide some additional context to the information in the liver injury *vs* non-liver injury cohort studies about the potential use of hematology data. These include the study of Liao *et al*[70], which demonstrated that liver injury correlated with inflammatory cytokine level, ALC, and DDIM; the study by Lei *et al*[69], which showed that liver injury correlated with disease severity and ALC; and the studies of Cai *et al*[67] and Jiang *et al*[68], which identified a high percentage of patients with liver failure in the severe disease cohorts, which differed from the non-severe cohorts in ALC and DDIM levels.

Five other retrospective cohort studies (Table 4) likewise demonstrated the potential usefulness of hematology data in COVID-19 disease and liver injury[72-76]. These included the study of Cao *et al*[72] which demonstrated that serum ferritin levels correlated with disease severity and degree of liver injury, as well as showed statistically significant differences in WBC, ANC, ALC, and DDIM between the two groups. Another study correlating elevated liver enzymes/liver injury with increased risk of COVID-19 disease recurrence noted significant differences in PLTs between patients with non-recurrent *vs* recurrent disease[73]. The study of Ding *et al*[74], which associated AST and direct bilirubin elevation with increased risk of mortality also noted significant differences in ALC, PLTs, and DDIM between the two groups. Lei *et al*[75] in a study examining peak levels of AST, ALC, ALP, and TBIL in patients with COVID-19 and liver injury noted that peak levels correlated with ANC, ALC, PLTS, and DDIM. Finally, Luan *et al*[76], who noted the correlation of COVID-19-related coagulopathy with liver injury, also found an associated significant difference in ALC, ANC, and DDIM between patients with and without coagulopathy.

***Additional analysis (study quality)***

Twenty-eight studies in our series contained control groups and could be evaluated using the NOS for cohort studies. Overall, 24/28 (86%)studies had a NOS in the high quality (7-9) range, 4/28 (14%) in the moderate quality (4-6) range, and no studies were rated in the low quality (0-3) range. Notably, for 24/28 (86%) papers, there was consensus in the initial evaluation by Frater JL and Wang T.

**DISCUSSION**

***Summary of evidence***

The purpose of this systematic review was to evaluate whether the hematologic parameters of importance in diagnosis and risk stratification in COVID-19 can be applied to the subpopulation with liver injury, and to determine whether the current state of the evidence supports whether SARS-CoV-2 patients should be categorized as having severe disease. A total of 32 studies met our inclusion criteria and were included in the analyses. The overall quality of the studies was strong, with 86% having an NOS ≥ 7. Based on our evaluation, WBCs, ANC, ALC, and HGB appear to the most useful parameters in addition to LFT to distinguish COVID-19 patients with liver injury from those without liver injury. Similarly, studies that analyzed severe *vs* non-severe COVID-19 cohorts showed that liver injury was present in a high proportion of patients with severe disease, who also had significant differences in ALC and DDIM. Studies focused on liver injury with other study designs likewise supported the association of liver injury with altered WBC, ANC, ALC, PLTs, and DDIM.

***Association of liver injury with abnormalities of hematologic parameters: Diagnosis and risk stratification***

Automated hematology data and basic coagulation testing is widely available, cost-effective, and can be performed with rapid turnaround time. In situations where this data is of proven utility, it can provide value to the clinical team, either alone or as a component of other clinical and laboratory testing predictive models, such as the Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II scoring systems, which are widely used in critical care medicine.

Increased WBC has been associated with severe disease in COVID-19, and in some cases with an increased neutrophil-to-lymphocyte ratio and increase in eosinophils[77,78]. In our study 8/12 studies showed a significant increase in WBC in COVID-19 patients with liver injury *vs* those without liver injury. Notably, all evaluated studies with > 100 patients (*n* = 5) in the liver injury group had a significant difference in WBC (*P* < 0.001), suggesting that the WBC is a useful addition to LFT for assessing liver function in COVID-19. However, the available data do not appear to support a role for WBC in risk stratification, as only 1/5 studies of non-severe *vs* severe disease demonstrated a significant difference in the WBC.

Lymphopenia, believed to be due to a defective host response, has been identified in COVID-19 patients and has been associated with increased risk of severe disease[2-4,79]. The overall performance of ALC as a biomarker of liver injury appears mixed, as it is not significantly different from COVID-19 patients without liver injury in 4/10 studies with > 100 liver injury patients. Likewise, 3/5 studies showed the ALC to be associated with severe disease and increased risk of liver injury.

Neutrophilia appears to be associated with cytokine storm and hyperinflammation, which has been implicated as a major factor in the pathophysiology of COVID-19. Accordingly, differences in the ANC have been noted in studies evaluating the roles of hematologic data in more generalized populations of COVID-19 patients[3,6,8,9,50,79]. In our study, altered ANC appears to be associated with liver injury in COVID-19, with 5/6 studies with > 100 participants with liver injury having significant differences in ANC compared to those without liver injury. Its usefulness for risk stratification is more difficult to interpret. Although only 1/4 non-severe *vs* severe COVID-19 studies demonstrated a difference in ANC, it has been associated with increased risk of COVID-associated coagulopathy, increased serum ferritin, and increased liver enzymes[72,75,76]. Thus, although ANC appears to be a useful maker of liver injury, its potential as a marker for disease stratification is unclear at this point.

Thrombocytopenia has been identified as a maker of severe COVID-19 and has been associated with consumptive coagulopathy[5,79]. In our study, the majority of studies of COVID-19 with liver injury *vs* those without liver injury did not identify significant difference in PLTs, with only 2/7 studies with > 100 patients in the liver injury group demonstrating significant differences in PLTS. Likewise, 0/4 studies of severe *vs* non-severe COVID-19 patients in our analysis demonstrated significant differences in PLTs. These results indicate that PLTs are not useful either for diagnosis or risk stratification in this group.

An association of decreased HGB with severe COVID-19 has been proposed, but is controversial due to the high heterogeneity of available data[80]. Interestingly, our data imply a potential role of HGB for assessment of liver function in COVID-19, with significant differences in hemoglobin detected in 5/5 studies of liver injury with > 100 participants. Unfortunately, HGB was analyzed in only 1 study in the severe *vs* non-severe study group[70], and a significant difference was not identified. Although these results are promising for the use of HGB as an adjunct to detection of liver injury, further work is necessary to determine whether HGB is a predictor of high risk in this population.

Acquired coagulopathies are a major feature of COVID-19, and a subset of patients develop disseminated intravascular coagulation and multiorgan failure[79,81,82]. In patients with liver injury, significant differences in DDIM were identified in 3/6 studies with > 100 participants; prolongation of PT was identified in 2/4 studies; and prolonged aPTT was present in 0/1 of these studies. In studies comparing non-severe to severe COVID-19 disease differences in DDIM level were identified in 3/3 studies and PT prolongation was identified in 1/1 study. These findings, although based on only a limited number of studies, imply that coagulopathy in COVID-19 is not limited to patients with liver injury and is associated with more severe disease.

***Limitations***

There were some limitations to this study. Despite an effort to comprehensively search the peer-reviewed medical literature, publications that did not mention liver injury in the title, abstract, or keywords of the papers may not have been included in the search results. Delays in indexing in the databases may also have contributed to papers not being identified in the search. Although some national and international organizations have worked to precisely define the term COVID-19 liver injury[83,84], the lack of precision, especially in papers published early in the pandemic, makes it challenging to confidently compare the results of individual studies.

**CONCLUSION**

We conducted a systematic review of the peer-reviewed literature regarding laboratory hematology data and their potential use in diagnosis and risk stratification in COVID-19 patients with liver injury. Based on our interpretation of the evidence, evaluation, WBC, ANC, ALC, and HGB may be of interest in addition to LFT in the distinction of patients with liver injury from those without. Since these markers are cited as markers of severe disease in many studies in the medical literature[1], this implies that COVID-19 patients are at increased risk of severe disease. This claim is supported by our evaluation of the medical literature that discusses liver injury in the context of non-severe *vs* severe disease. Our findings support the conclusion that WBC, ANC, ALC, and HGB may be useful for diagnosis and risk stratification in the subset of COVID-19 patients with liver failure, as they are for the general population of patients infected by SARS-CoV-2. Other hematology parameters, such as PLTs, which are widely used in critical care medicine and are a component of the SOFA score, appear to be less relevant in liver failure patients with COVID-19. Our evaluation of the literature concludes that, although it has a high methodological quality, it is limited by the lack of a clear definition for COVID-19 liver injury, and by the lack of comprehensive reporting of laboratory data in many epidemiological studies. The limited statistical power of a high fraction of these studies, and the lack of statistical analysis of hematologic parameters beyond the univariate t-test are further issues. Further work with larger numbers of patients and more robust data analysis may be of interest to determine the precise role of hematologic parameters in the diagnosis and stratification of COVID-19 patients with liver injury.

**ARTICLE HIGHLIGHTS**

***Research background***

Hematology laboratory testing has an established role in risk stratification in patients with coronavirus disease 2019 (COVID-19) disease. Liver injury is common in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The utility of hematology laboratory data in diagnosis and risk stratification of patients with COVID-19-related liver injury is unclear.

***Research motivation***

To what degree are the abnormalities in hematologic parameters seen in the general population of patients with COVID-19 also seen in the subpopulation of patients with associated liver injury? Is liver injury in COVID-19 indicative of severe disease. Does liver injury correlate with hematologic markers of severe disease? What is the quality of literature that addresses these questions?

***Research objectives***

The objectives of this study were: To determine the extent to which previously reported hematologic abnormalities are seen in patients with COVID-19-associated liver injury; to assess whether liver injury in COVID-19 is a sign of severe disease, and the extent to which liver injury correlates with markers of severe disease; and based on the extant literature, to determine the quality of this evidence.

***Research methods***

This study was conducted as a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review. We extracted information from cohort studies related to the topic of liver injury in COVID-19 in which laboratory hematology data were included.

***Research results***

In all, 32 articles were included in the systematic review, which consisted of 22 articles with a cohort of COVID-19 patients with liver injury; 5 comparing non-severe *vs* severe COVID-19 populations in which liver injury was addressed and 5 other cohort studies with a focus on liver injury. White blood cell count, absolute neutrophil count, absolute lymphocyte count (ALC), and hemoglobin were the parameters most useful to distinguish COVID-19 with liver injury from COVID-19 without liver injury. ALC and d-dimer were potentially useful in distinguishing non-severe from severe COVID-19. Liver injury was more frequently seen in cohorts with severe disease. Most studies were of high quality (24/48, 86%) with 4/28 (14%)of moderate quality and 0 of low quality.

***Research conclusions***

The use of select hematologic parameters in diagnosis and risk stratification of liver injury in COVID-19 patients appears warranted. The relevant literature is high quality, but is limited by the small number of studies with high statistical power and the variable definition of COVID-19 liver injury in the literature.

***Research perspectives***

Future studies, preferably with a prospective design, large numbers of patients, and rigorous definition of liver injury would be useful to validate these findings.

**REFERENCES**

1 **Bell R**, Zini G, d'Onofrio G, Rogers HJ, Lee YS, Frater JL. The hematology laboratory's response to the COVID-19 pandemic: A scoping review. *Int J Lab Hematol* 2021; **43**: 148-159 [PMID: 33180380 DOI: 10.1111/ijlh.13381]

2 **Lippi G**, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. *Clin Chem Lab Med* 2020; **58**: 1063-1069 [PMID: 32191623 DOI: 10.1515/cclm-2020-0240]

3 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

4 **Lippi G**, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. *Clin Chem Lab Med* 2020; **58**: 1131-1134 [PMID: 32119647 DOI: 10.1515/cclm-2020-0198]

5 **Lippi G**, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta* 2020; **506**: 145-148 [PMID: 32178975 DOI: 10.1016/j.cca.2020.03.022]

6 **Fan BE**, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, Mucheli SS, Kuperan P, Ong KH. Hematologic parameters in patients with COVID-19 infection. *Am J Hematol* 2020; **95**: E131-E134 [PMID: 32129508 DOI: 10.1002/ajh.25774]

7 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

8 **Mehta P**, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033-1034 [PMID: 32192578 DOI: 10.1016/S0140-6736(20)30628-0]

9 **Qin C**, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020; **71**: 762-768 [PMID: 32161940 DOI: 10.1093/cid/ciaa248]

10 **Cadranel JF**, Reboux N, Nousbaum JB. COVID-19: an emergent cause of liver injury? *Eur J Gastroenterol Hepatol* 2021; **33**: 1-3 [PMID: 32639418 DOI: 10.1097/MEG.0000000000001824]

11 **Napodano C**, Pocino K, Stefanile A, Marino M, Miele L, Gulli F, Basile V, Pandolfi F, Gasbarrini A, Rapaccini GL, Basile U. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. *Scand J Immunol* 2021; **93**: e12977 [PMID: 32931622 DOI: 10.1111/sji.12977]

12 **Lv XH**, Yang JL, Deng K. The Topic of COVID-19-Related Liver Injury Needs More Rigorous Research. *Clin Gastroenterol Hepatol* 2020; **18**: 2848 [PMID: 32371168 DOI: 10.1016/j.cgh.2020.04.073]

13 **Ye Z**, Song B. COVID-19 Related Liver Injury: Call for International Consensus. *Clin Gastroenterol Hepatol* 2020; **18**: 2848-2851 [PMID: 32425707 DOI: 10.1016/j.cgh.2020.05.013]

14 **Ye Z**, Song B. Liver injury in COVID-19: Diagnosis and associated factors. *Liver Int* 2020; **40**: 2040-2041 [PMID: 32359220 DOI: 10.1111/liv.14501]

15 **Li G**, Yang Y, Gao D, Xu Y, Gu J, Liu P. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. *Int J Med Sci* 2021; **18**: 1285-1296 [PMID: 33526990 DOI: 10.7150/ijms.51174]

16 **Agarwal A**, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and Liver Manifestations of COVID-19. *J Clin Exp Hepatol* 2020; **10**: 263-265 [PMID: 32405183 DOI: 10.1016/j.jceh.2020.03.001]

17 **Lenti MV**, Borrelli de Andreis F, Pellegrino I, Klersy C, Merli S, Miceli E, Aronico N, Mengoli C, Di Stefano M, Cococcia S, Santacroce G, Soriano S, Melazzini F, Delliponti M, Baldanti F, Triarico A, Corazza GR, Pinzani M, Di Sabatino A; Internal Medicine Covid-19 Team. Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy. *Intern Emerg Med* 2020; **15**: 1399-1407 [PMID: 32651938 DOI: 10.1007/s11739-020-02425-w]

18 **Ali N**. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients? *Clin Res Hepatol Gastroenterol* 2020; **44**: e84-e86 [PMID: 32471656 DOI: 10.1016/j.clinre.2020.05.002]

19 **Cai Q**, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]

20 **Alqahtani SA**, Schattenberg JM. Liver injury in COVID-19: The current evidence. *United European Gastroenterol J* 2020; **8**: 509-519 [PMID: 32450787 DOI: 10.1177/2050640620924157]

21 **Fan Z**, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol* 2020; **18**: 1561-1566 [PMID: 32283325 DOI: 10.1016/j.cgh.2020.04.002]

22 **Kumar A**, Kumar P, Dungdung A, Kumar Gupta A, Anurag A, Kumar A. Pattern of liver function and clinical profile in COVID-19: A cross-sectional study of 91 patients. *Diabetes Metab Syndr* 2020; **14**: 1951-1954 [PMID: 33039937 DOI: 10.1016/j.dsx.2020.10.001]

23 **Saini RK**, Saini N, Ram S, Soni SL, Suri V, Malhotra P, Kaur J, Verma I, Sharma S, Zohmangaihi D. COVID-19 associated variations in liver function parameters: a retrospective study. *Postgrad Med J* 2020 [PMID: 33184141 DOI: 10.1136/postgradmedj-2020-138930]

24 **Xu L**, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int* 2020; **40**: 998-1004 [PMID: 32170806 DOI: 10.1111/liv.14435]

25 **Ji D**, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol* 2020; **73**: 451-453 [PMID: 32278005 DOI: 10.1016/j.jhep.2020.03.044]

26 **Xie H**, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int* 2020; **40**: 1321-1326 [PMID: 32239591 DOI: 10.1111/liv.14449]

27 **Zhang Y**, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver Int* 2020; **40**: 2095-2103 [PMID: 32239796 DOI: 10.1111/liv.14455]

28 **Sun J**, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. *Liver Int* 2020; **40**: 1278-1281 [PMID: 32251539 DOI: 10.1111/liv.14470]

29 **Li G**. Aspartate aminotransferase: A prognostic marker rather than a specific liver injury marker in COVID-19. *J Infect* 2020; **81**: e155 [PMID: 32525000 DOI: 10.1016/j.jinf.2020.06.007]

30 **Bloom PP**, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, Schaefer E, Chung RT. Liver Biochemistries in Hospitalized Patients With COVID-19. *Hepatology* 2021; **73**: 890-900 [PMID: 32415860 DOI: 10.1002/hep.31326]

31 **Bertolini A**, van de Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. *Hepatology* 2020; **72**: 1864-1872 [PMID: 32702162 DOI: 10.1002/hep.31480]

32 **Li J**, Fan JG. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. *J Clin Transl Hepatol* 2020; **8**: 13-17 [PMID: 32274341 DOI: 10.14218/JCTH.2020.00019]

33 **Lizardo-Thiebaud MJ**, Cervantes-Alvarez E, Limon-de la Rosa N, Tejeda-Dominguez F, Palacios-Jimenez M, Méndez-Guerrero O, Delaye-Martinez M, Rodriguez-Alvarez F, Romero-Morales B, Liu WH, Huang CA, Kershenobich D, Navarro-Alvarez N. Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients. *Semin Liver Dis* 2020; **40**: 321-330 [PMID: 32886936 DOI: 10.1055/s-0040-1715108]

34 **Morgan K**, Samuel K, Vandeputte M, Hayes PC, Plevris JN. SARS-CoV-2 Infection and the Liver. *Pathogens* 2020; **9** [PMID: 32486188 DOI: 10.3390/pathogens9060430]

35 **Nardo AD**, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. *Liver Int* 2021; **41**: 20-32 [PMID: 33190346 DOI: 10.1111/liv.14730]

36 **Wu J**, Song S, Cao HC, Li LJ. Liver diseases in COVID-19: Etiology, treatment and prognosis. *World J Gastroenterol* 2020; **26**: 2286-2293 [PMID: 32476793 DOI: 10.3748/wjg.v26.i19.2286]

37 **Yang HY**, Jin B, Mao YL. Liver injury in COVID-19: What do we know now? *Hepatobiliary Pancreat Dis Int* 2020; **19**: 407-408 [PMID: 32753332 DOI: 10.1016/j.hbpd.2020.07.009]

38 **Aguila EJT**, Cua IHY, Dumagpi JEL, Francisco CPD, Raymundo NTV, Sy-Janairo MLL, Cabral-Prodigalidad PAI, Lontok MAD. COVID-19 and its effects on the digestive system and endoscopy practice. *JGH Open* 2020; **4**: 324-331 [PMID: 32514432 DOI: 10.1002/jgh3.12358]

39 **Chaibi S**, Boussier J, Hajj WE, Abitbol Y, Taieb S, Horaist C, Jouannaud V, Wang P, Piquet J, Maurer C, Lahmek P, Nahon S. Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort. *Clin Res Hepatol Gastroenterol* 2020: 101556 [PMID: 33139241 DOI: 10.1016/j.clinre.2020.10.002]

40 **Da BL**, Mitchell RA, Lee BT, Perumalswami P, Im GY, Agarwal R, Schiano TD, Dieterich D, Saberi B. Kinetic patterns of liver enzyme elevation with COVID-19 in the USA. *Eur J Gastroenterol Hepatol* 2020; **32**: 1466-1469 [PMID: 32501877 DOI: 10.1097/MEG.0000000000001792]

41 **Wang Q**, Zhao H, Liu LG, Wang YB, Zhang T, Li MH, Xu YL, Gao GJ, Xiong HF, Fan Y, Cao Y, Ding R, Wang JJ, Cheng C, Xie W. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. *Mil Med Res* 2020; **7**: 28 [PMID: 32507110 DOI: 10.1186/s40779-020-00256-6]

42 **Yip TC**, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, Tse YK, Hui DS, Chan HL, Wong GL. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. *Gut* 2021; **70**: 733-742 [PMID: 32641471 DOI: 10.1136/gutjnl-2020-321726]

43 **Gopalakrishnan S**, Ganeshkumar P. Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare. *J Family Med Prim Care* 2013; **2**: 9-14 [PMID: 24479036 DOI: 10.4103/2249-4863.109934]

44 **Cook DJ**, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med* 1997; **126**: 376-380 [PMID: 9054282 DOI: 10.7326/0003-4819-126-5-199703010-00006]

45 **Wells GA,** Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. [cited 10 January 2021]. Available from: URL: http://www.ohri.ca/programs/clinical\_epidemiology/oxford.htm

46 **Abe K**, Yamamoto T, Matsumoto K, Kikuchi K, Miura R, Tachizawa N, Asaoka Y, Takezawa T, Matsunaga N, Obi S, Tanaka A. Clinical Features and Liver Injury in Patients with COVID-19 in the Japanese Population. *Intern Med* 2020; **59**: 2353-2358 [PMID: 32999264 DOI: 10.2169/internalmedicine.5777-20]

47 **An YW**, Song S, Li WX, Chen YX, Hu XP, Zhao J, Li ZW, Jiang GY, Wang C, Wang JC, Yuan B, Liu HQ. Liver function recovery of COVID-19 patients after discharge, a follow-up study. *Int J Med Sci* 2021; **18**: 176-186 [PMID: 33390786 DOI: 10.7150/ijms.50691]

48 **Anastasiou OE**, Korth J, Herbstreit F, Witzke O, Lange CM. Mild versus Severe Liver Injury in SARS-CoV-2 Infection. *Dig Dis* 2021; **39**: 52-57 [PMID: 32777784 DOI: 10.1159/000510758]

49 **Cardoso FS**, Pereira R, Germano N. Liver injury in critically ill patients with COVID-19: a case series. *Crit Care* 2020; **24**: 190 [PMID: 32366282 DOI: 10.1186/s13054-020-02924-4]

50 **Chen F**, Chen W, Chen J, Xu D, Xie W, Wang X, Xie Y. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. *Ann Hepatol* 2021; **21**: 100267 [PMID: 33053426 DOI: 10.1016/j.aohep.2020.09.011]

51 **Chen LY**, Chu HK, Bai T, Tu SJ, Wei Y, Li ZL, Hu LL, Zhu R, Zhang L, Han CQ, Xiao L, He Q, Song J, Liu WH, Zhu QJ, Chen H, Yang L, Hou XH. Liver damage at admission is an independent prognostic factor for COVID-19. *J Dig Dis* 2020; **21**: 512-518 [PMID: 32713118 DOI: 10.1111/1751-2980.12925]

52 **Chu H**, Bai T, Chen L, Hu L, Xiao L, Yao L, Zhu R, Niu X, Li Z, Zhang L, Han C, Song S, He Q, Zhao Y, Zhu Q, Chen H, Schnabl B, Yang L, Hou X. Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. *Front Med (Lausanne)* 2020; **7**: 584342 [PMID: 33195339 DOI: 10.3389/fmed.2020.584342]

53 **Da BL**, Kushner T, El Halabi M, Paka P, Khalid M, Uberoi A, Lee BT, Perumalswami PV, Rutledge SM, Schiano TD, Friedman S, Saberi B. Liver Injury in Hospitalized Patients with COVID-19 Correlates with Hyper Inflammatory Response and Elevated IL-6. *Hepatol Commun* 2020; **5**: 177-188 [PMID: 33230491 DOI: 10.1002/hep4.1631]

54 **Fiel MI**, El Jamal SM, Paniz-Mondolfi A, Gordon RE, Reidy J, Bandovic J, Advani R, Kilaru S, Pourmand K, Ward S, Thung SN, Schiano T. Findings of Hepatic Severe Acute Respiratory Syndrome Coronavirus-2 Infection. *Cell Mol Gastroenterol Hepatol* 2021; **11**: 763-770 [PMID: 32992052 DOI: 10.1016/j.jcmgh.2020.09.015]

55 **Huang H**, Chen S, Li H, Zhou XL, Dai Y, Wu J, Zhang J, Shao L, Yan R, Wang M, Wang J, Tu Y, Ge M. The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan. *Aliment Pharmacol Ther* 2020; **52**: 1051-1059 [PMID: 32697870 DOI: 10.1111/apt.15962]

56 **Lagana SM**, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, Del Portillo A, De Michele S, de Gonzalez AK, Saqi A, Khairallah P, Chong AM, Park H, Uhlemann AC, Lefkowitch JH, Verna EC. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. *Mod Pathol* 2020; **33**: 2147-2155 [PMID: 32792598 DOI: 10.1038/s41379-020-00649-x]

57 **Li X**, Zhang ZC, Zhang PL. Severe COVID-19 patients with liver injury: a seven-case series. *Eur Rev Med Pharmacol Sci* 2020; **24**: 7855-7860 [PMID: 32744713 DOI: 10.26355/eurrev\_202007\_22290]

58 **Meszaros M**, Meunier L, Morquin D, Klouche K, Fesler P, Malezieux E, Makinson A, Le Moing V, Reynes J, Pageaux GP. Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry? *Liver Int* 2020; **40**: 1860-1864 [PMID: 32495496 DOI: 10.1111/liv.14557]

59 **Mishra K**, Naffouj S, Gorgis S, Ibrahim H, Gill S, Fadel R, Chatfield A, Tang A, Salgia R. Liver Injury as a Surrogate for Inflammation and Predictor of Outcomes in COVID-19. *Hepatol Commun* 2021; **5**: 24-32 [PMID: 33437898 DOI: 10.1002/hep4.1586]

60 **Phipps MM**, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. *Hepatology* 2020; **72**: 807-817 [PMID: 32473607 DOI: 10.1002/hep.31404]

61 **Piano S**, Dalbeni A, Vettore E, Benfaremo D, Mattioli M, Gambino CG, Framba V, Cerruti L, Mantovani A, Martini A, Luchetti MM, Serra R, Cattelan A, Vettor R, Angeli P; COVID-LIVER study group. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. *Liver Int* 2020; **40**: 2394-2406 [PMID: 32526083 DOI: 10.1111/liv.14565]

62 **Qi X**, Liu C, Jiang Z, Gu Y, Zhang G, Shao C, Yue H, Chen Z, Ma B, Liu D, Zhang L, Wang J, Xu D, Lei J, Li X, Huang H, Wang Y, Liu H, Yang J, Pan H, Liu W, Wang W, Li F, Zou S, Zhang H, Dong J. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. *J Hepatol* 2020; **73**: 455-458 [PMID: 32305291 DOI: 10.1016/j.jhep.2020.04.010]

63 **Gholizadeh P**, Safari R, Marofi P, Zeinalzadeh E, Pagliano P, Ganbarov K, Esposito S, Khodadadi E, Yousefi M, Samadi Kafil H. Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19). *J Inflamm Res* 2020; **13**: 285-292 [PMID: 32669866 DOI: 10.2147/JIR.S257078]

64 **Sadeghi A**, Eslami P, Dooghaie Moghadam A, Pirsalehi A, Shojaee S, Jalilian Khave L, Sanadgol G, Hasanzade T, Shirini D, Asadzadeh Aghdaei H, Abdi S, Zali MR. Risk factors related to liver injury in non-Intensive Care Unit admitted patients infected with COVID-19: A retrospective study of 102 patients. *Caspian J Intern Med* 2020; **11**: 520-526 [PMID: 33425269 DOI: 10.22088/cjim.11.0.520]

65 **Tsutsumi T**, Saito M, Nagai H, Yamamoto S, Ikeuchi K, Lim LA, Adachi E, Koga M, Okushin K, Akai H, Kunimatsu A, Yotsuyanagi H. Association of coagulopathy with liver dysfunction in patients with COVID-19. *Hepatol Res* 2021; **51**: 227-232 [PMID: 33047431 DOI: 10.1111/hepr.13577]

66 **Wang M**, Yan W, Qi W, Wu D, Zhu L, Li W, Wang X, Ma K, Ni M, Xu D, Wang H, Chen G, Yu H, Ding H, Xing M, Han M, Luo X, Chen T, Guo W, Xi D, Ning Q. Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. *Hepatol Int* 2020; **14**: 723-732 [PMID: 33026573 DOI: 10.1007/s12072-020-10075-5]

67 **Cai Q**, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy* 2020; **75**: 1742-1752 [PMID: 32239761 DOI: 10.1111/all.14309]

68 **Jiang S**, Wang R, Li L, Hong D, Ru R, Rao Y, Miao J, Chen N, Wu X, Ye Z, Hu Y, Xie M, Zuo M, Lu X, Qiu Y, Liang T. Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. *Front Med (Lausanne)* 2020; **7**: 347 [PMID: 32656222 DOI: 10.3389/fmed.2020.00347]

69 **Lei P**, Zhang L, Han P, Zheng C, Tong Q, Shang H, Yang F, Hu Y, Li X, Song Y. Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury. *Hepatol Int* 2020; **14**: 733-742 [PMID: 32886333 DOI: 10.1007/s12072-020-10087-1]

70 **Liao S**, Zhan K, Gan L, Bai Y, Li J, Yuan G, Cai Y, Zhang A, He S, Mei Z. Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients. *Signal Transduct Target Ther* 2020; **5**: 255 [PMID: 33130825 DOI: 10.1038/s41392-020-00363-9]

71 **Yang R**, Gui X, Ke H, Gao S, Luo M, Xiong Y. The indicative role of markers for liver injury on the severity and prognosis of coronavirus disease 2019 patients. *Eur J Gastroenterol Hepatol* 2020 [PMID: 33136731 DOI: 10.1097/MEG.0000000000001968]

72 **Cao P**, Wu Y, Wu S, Wu T, Zhang Q, Zhang R, Wang Z, Zhang Y. Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia. *Biomarkers* 2021; **26**: 207-212 [PMID: 33284041 DOI: 10.1080/1354750X.2020.1861098]

73 **Chen LZ**, Lin ZH, Chen J, Liu SS, Shi T, Xin YN. Can elevated concentrations of ALT and AST predict the risk of 'recurrence' of COVID-19? *Epidemiol Infect* 2020; **148**: e218 [PMID: 32951624 DOI: 10.1017/S0950268820002186]

74 **Ding ZY**, Li GX, Chen L, Shu C, Song J, Wang W, Wang YW, Chen Q, Jin GN, Liu TT, Liang JN, Zhu P, Zhu W, Li Y, Zhang BH, Feng H, Zhang WG, Yin ZY, Yu WK, Yang Y, Zhang HQ, Tang ZP, Wang H, Hu JB, Liu JH, Yin P, Chen XP, Zhang B; Tongji Multidisciplinary Team for Treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19. *J Hepatol* 2020 [PMID: 33347952 DOI: 10.1016/j.jhep.2020.12.012]

75 **Lei F**, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Zhou J, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu L, Chen G, Li H, Huang X, Zhang BH, Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. *Hepatology* 2020; **72**: 389-398 [PMID: 32359177 DOI: 10.1002/hep.31301]

76 **Luan YY**, Liu Y, Liu XY, Yu BJ, Chen RL, Peng M, Ren D, Li HL, Huang L, Liu Y, Li JX, Feng YW, Wu M. Coronavirus disease 2019 (COVID-19) associated coagulopathy and its impact on outcomes in Shenzhen, China: A retrospective cohort study. *Thromb Res* 2020; **195**: 62-68 [PMID: 32659462 DOI: 10.1016/j.thromres.2020.07.015]

77 **Anurag A**, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. *Diabetes Metab Syndr* 2020; **14**: 2099-2102 [PMID: 33160224 DOI: 10.1016/j.dsx.2020.10.029]

78 **Yuan J**, Zou R, Zeng L, Kou S, Lan J, Li X, Liang Y, Ding X, Tan G, Tang S, Liu L, Liu Y, Pan Y, Wang Z. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. *Inflamm Res* 2020; **69**: 599-606 [PMID: 32227274 DOI: 10.1007/s00011-020-01342-0]

79 **Frater JL**, Zini G, d'Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. *Int J Lab Hematol* 2020; **42 Suppl 1**: 11-18 [PMID: 32311826 DOI: 10.1111/ijlh.13229]

80 **Lippi G**, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. *Hematol Transfus Cell Ther* 2020; **42**: 116-117 [PMID: 32284281 DOI: 10.1016/j.htct.2020.03.001]

81 **Tang N**, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020; **18**: 844-847 [PMID: 32073213 DOI: 10.1111/jth.14768]

82 **Yin S**, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. *J Thromb Thrombolysis* 2020 [PMID: 32246317 DOI: 10.1007/s11239-020-02105-8]

83 **National Health Commission and State Administration of Traditional Chinese Medicine**. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6), 2020. [cited 10 January 2021]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.

84 Diagnosis and treatment plan of Corona Virus Disease 2019 (tentative sixth edition). *Glob Health J* 2020; **4**: 1-5 [PMID: 32292830 DOI: 10.1016/j.glohj.2020.03.001]

**Footnotes**

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**PRISMA 2009 Checklist statement:** The manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** International Society of Laboratory Hematology.

**Peer-review started:** January 28, 2021

**First decision:** February 24, 2021

**Article in press:** April 23, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Braga MB, Duan Z **S-Editor:** Wang JL **L-Editor:** Filipodia **P-Editor:** Li JH

**Figure Legends**



**Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 flow diagram.**

**Table 1 Studies with a coronavirus disease 2019 (+) cohort with liver injury provided as a distinct group**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Number of patients** | **% of total patients** | **Age, mean** | **% male** | **Setting** | **Study group inclusion criteria** | **Control group** | **Evaluated parameters** | **NOS** |
| Abe *et al*[46] | Japan | 15 | 68 | 47 | 59 | Hospitalized patients | ALT OR GGT over ULN | COVID+ | WBC, ALC, HGB | 8 |
| An *et al*[47] | China | 51 | 21 | 52 | 45.1 | Hospitalized patients | AST OR ALT over ULN | COVID+ | WBC, ALC, ANC, DDIM | 8 |
| Anastasiou *et al*[48] | Germany | 82 | 56.2 | 64.5 | 74 | Hospitalized patients | ALT OR BILI over ULN | COVID+ | WBC, INR | 6 |
|  |  | 11 | 6.8 | 51 | 100 |  | EASL ALF criteria (see ref[10]) |  |  |  |
| Cardoso *et al*[49] | Portugal | 20 | 100 | 67 | 90 | ICU | GGT OR/AST OR/ALT over ULN | None | SOFA, APACHE II |  NA |
| Chen *et al*[50] | China | 227 | 38 | 56 | 63 | Hospitalized patients | ALT OR AST OR GGT over ULN | COVID+ | ALC, DDIM | 9 |
| Chen *et al*[51] | China | 301 | 59 | 62 | 82 | Hospitalized patients | AST OR ALT OVER ULN/ OR elevated ALP/GGT over ULN | COVID+ | WBC, ALC, ANC, PLTs, PT, PTT, INR | 7 |
| Chu *et al*[52] | China | 429 | 51 | 61 | 65 | Hospitalized patients | ALT/ALP ratio over ULN | COVID+ | WBC, ALC, ANC, PLTs, HGB, DDIM, PT, INR | 7 |
| Da *et al*[53] | U.S. | 109 | 62 | 61 | 78 | Hospitalized patients | AST or ALT ≥ 3 times ULN | COVID+ | DDIM, PT, INR | 8 |
| Fiel *et al*[54] | United States | 2 | 100 |  NA | 50 | Hospitalized patients | Biopsy proven disease without pneumonia | None | DDIM |  NA |
| Huang *et al*[55] | China | 253 | 37.5 | 58 | 59 | Hospitalized patients | AST, ALT, TBIL over ULN | COVID+ | WBC, ALC, PLTs, HGB | 5 |
|  |  | 52 | 7.7 | 51.5 | 81 |  | ALT ≥ 3 times ULN |  |  |  |
| Lagana *et al*[56] | United States | 11 | 100 | 70 | 70 | NS | PCR testing of liver  | None | DDIM |  NA |
| Li *et al*[57] | China | 7 |  NS | 61 | 43 | Hospitalized patients | AST or ALT over ULN | None | WBC, ALC, ANC, DDIM, HGB |  NA |
| Meszaros *et al*[58] | France | 156 | 66.7 | 66.5 | 73 | Hospitalized patients | AST OR ALT OR GGT over ULN | COVID+ | ALC, PLTs, DDIM | 7 |
| Mishra *et al*[59] | United States | 184 | 52.9 | 62.7 | 58 | Hospitalized patients | AST OR ALT over ULN | COVID+ | WBC, ALC, ANC, HGB | 7 |
| Phipps *et al*[60] | United States | 1784 |  | 66 | 73 | Hospitalized patients | ALT > 1-2× ULN | COVID+ | WBC, ALC, ANC, PLTs, DDIM, HGB | 8 |
|  |  | 344 |  | 61 |  |  | ALT 2-5× ULN |  |  |  |
|  |  | 145 |  | 63 |  |  | ALT > 5× ULN |  |  |  |
| Piano *et al*[61] | Italy | 329 | 58 | 66 | 63 | Hospitalized patients | AST OR ALT OR GGT OR ALP OR BILI > ULN | COVID+ | WBC, ALC, ANC, PLTs, DDIM, INR | 7 |
| Qi *et al*[62] | China | 32 | 46 | 41 | 72 | Hospitalized patients | AST OR ALT OR BILI over ULN | COVID+ | WBC, ALC, ANC | 6 |
| Sadeghi *et al*[64] | Iran | 65 | 64 | 55 | 64 | Non-ICU hospitalized | AST OR ALT OR BILI over ULN | COVID+ | WBC, ALC, ANC | 9 |
| Safari *et al*[63] | Iran | 41 | 17 | 52 | 31 | Hospitalized patients | ALT above ULN | COVID+ | WBC, PLTs, HGB | 8 |
| Tsutsumi *et al*[65] | Japan | 31 | 52 | 46 | 84 | Hospitalized patients | ALT ≥ 40 U/L | COVID+ | WBC, ALC, PLTs, DDIM, PT | 8 |
| Wang *et al*[66] | China | 303 | 46.1 | 62 | 63.4 | Hospitalized patients | ALT OR GGT OR BILI over ULN | COVID+ | WBC, ALC, ANC, PLTs, HGB, PT | 8 |
| Xie *et al*[26] | China | 29 | 26.9 | 62 | 72.4 | Non-ICU hospitalized | AST OR ALT OR BILI over ULN | COVID+ | WBC, ALC, ANC, DDIM | 8 |

ALC: Absolute lymphocyte count; ALP: Alkaline phosphatase; ALT: Alanine transaminase; ANC: Absolute neutrophil count; APACHE II: Acute Physiology and Chronic Health Evaluation II scoring system; AST: Aspartate transaminase; BILI: Bilirubin; COVID-19: Coronavirus disease 2019; DDIM: D-dimer; EASL ALF criteria: European Association for the Study of the Liver Acute Liver Failure Guidelines; GGT: Gamma-glutamyltransferase; HGB: Hemoglobin; INR: International normalized ratio; NA: Not applicable; NOS: Newcastle-Ottawa Scale; NS: Not stated; PLT: Platelet count; PT: Prothrombin time; PTT: Partial thromboplastin time; SOFA: Sequential Organ Failure Assessment scoring system; ULN: Upper limit of normal; WBC: White blood cell count.

**Table 2 Summary of statistical data from studies comparing liver injury *vs* non-liver injury**

|  |  |  |
| --- | --- | --- |
| **LFT criteria** | **Parameter** | **Significance** |
|  **NS** | **< 0.05** | **< 0.01** | **< 0.001** |
| LFT > ULN | WBC | 4 | 2 | 0 | 6 |
|  | ANC | 4 | 1 | 0 | 4 |
|  | ALC | 4 | 2 | 1 | 5 |
|  | HGB | 4 | 2 | 0 | 5 |
|  | PLT | 4 | 2 | 0 | 2 |
|  | DDIM | 4 | 2 | 1 | 0 |
|  | PT | 4 | 2 | 1 | 0 |
|  | PTT | 4 | 2 | 0 | 0 |
|  | INR | 4 | 2 | 1 | 0 |
| LFT > 2 × ULN | WBC | 4 | 2 | 0 | 3 |
|  | ANC | 4 | 2 | 0 | 1 |
|  | ALC | 4 | 2 | 1 | 1 |
|  | HGB | 4 | 2 | 0 | 2 |
|  | PLT | 4 | 2 | 0 | 1 |
|  | DDIM | 4 | 2 | 0 | 1 |
|  | PT | 4 | 2 | 0 | 0 |
|  | INR | 4 | 2 | 0 | 0 |
| Studies with > 100 patients in high LFT cohort | WBC | 0 | 0 | 0 | 5 |
|  | ANC | 1 | 0 | 0 | 5 |
|  | ALC | 4 | 0 | 1 | 5 |
|  | HGB | 0 | 0 | 0 | 5 |
|  | PLT | 5 | 0 | 0 | 2 |
|  | DDIM | 3 | 0 | 0 | 3 |
|  | PT | 2 | 1 | 1 | 0 |
|  | PTT | 1 | 0 | 0 | 0 |

Numbers indicate number of studies.ALC: Absolute lymphocyte count; ANC: Absolute neutrophil count; DDIM: D-dimer; HGB: Hemoglobin; INR: International normalized ratio; LFT: Liver function test; NS: Not significant; PLT: Platelet count; PT: Prothrombin time; PTT: Partial thromboplastin time; ULN: Upper limit of normal; WBC: White blood cell count.

**Table 3 Studies comparing coronavirus disease 2019 patients with severe *vs* non-severe disease**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Patients with severe disease (% of total)** | **Setting** | **Definition of SEVERE disease** | **Definition of liver Injury** | **Evaluated parameters** | **Summary of main findings** | **NOS** |
| Cai *et al*[67] | China | 58 (19.5) | Hospitalized patients | Radiography supporting severe disease | ALT OR AST > 3 times ULN or GGT or TBIL > 2 times ULN | WBC, ANC, ALC, DDIM | LFT significantly elevated in severe cohort at admission | 8 |
| Jiang *et al*[68] | China | 27 (20.6) | Hospitalized patients | Chinese National Health Committee criteria (see ref[82]) | AST OR ALT OR ALP OR TBIL > 5 times ULN | WBC, ANC, ALC, PLTS, HGB | Liver injury in 81% of severe cohort over course of hospitalization; slow recovery from liver injury compared to other cohorts | 7 |
| Lei *et al*[69] | China | 48 Severe cohort | Hospitalized patients | National Health Commission of the People’s Republic of China and National Administration of Traditional Chinese Medicine of the People’s Republic of China criteria (see ref[83]) | CT showing liver hypodensity and pericholecystic fat stranding | WBC, ALC, PLTS | Severity of COVID-19 disease correlated with liver function | 7 |
|  | China | 48 Critical cohort | Hospitalized patients | Health Commission of the People’s Republic of China and National Administration of Traditional Chinese Medicine of the People’s Republic of China criteria (see ref[83]) | CT showing liver hypodensity and pericholecystic fat stranding | WBC, ALC, PLTS | Severity of COVID-19 disease correlated with liver function |  |
| Liao *et al*[70] | China | 29 (15.1) | Hospitalized patients | National Guidelines for 2019 novel coronavirus-associated pneumonia (the fifth revised version) | AST OR ALT OR TBIL over ULN | WBC, ANC, ALC, HGB, DDIM | Liver injury in high percentages of patients from both groups; correlated with inflammatory cytokine levels | 7 |
| Yang *et al*[71] | China | 215 (72.9) | Hospitalized patients | WHO criteria (see ref[8] from[68]) | AST > 1.5 times ULN | WBC, ANC, ALC, PLT, DDIM, PT | AST and GGT levels correlated with disease severity | 7 |

ALC: Absolute lymphocyte count; ALT: Alanine transaminase; ANC: Absolute neutrophil count; AST: Aspartate transaminase; COVID-19: Coronavirus disease 2019; CT: Computerized tomography; DDIM: D-dimer; GGT: Gamma-glutamyltransferase; HGB: Hemoglobin; NOS: Newcastle-Ottawa Score; PLT: Platelet count; PT: Prothrombin time; TBIL: Total bilirubin; WBC: White blood cell count; WHO: World Health Organization; ULN: Upper limit of normal.

**Table 4 Other retrospective cohort studies**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Setting** | **Evaluated parameters** | **Comparison** | **Summary of main findings** | **NOS** |
| Cao *et al*[72] | China | Hospitalized patients | WBC, ANC, ALC, DDIM | Elevated ferritin *vs* disease controls | Elevated ferritin corelated with disease severity and degree of liver injury | 7 |
| Chen *et al*[73] | China | Hospitalized patients | ANC, ALC, PLT, DDIM | Recurrent cases *vs* disease controls | Elevated AST and ALT are predictive of COVID-19 recurrence | 7 |
| Ding *et al*[74] | China | Hospitalized patients | ALC, PLT, DDIM | Deceased *vs* discharged  | Abnormal AST and D-Bil were independent predictors of mortality | 7 |
| Lei *et al*[75] | China | Hospitalized patients | ANC, ALC, PLT, DDIM | Comparison of parameters for peak levels of each LFT | Associated ANC, ALC, PLT, and DDIM with peak levels of AST, ALC, ALP, and TBIL | 6 |
| Luan *et al*[76] | China | ICU hospitalized | WBC, HGB, ANC, ALC, PLTS, DDIM, PT, PTT, INR | CAC *vs* non-CAC | CAC correlates with liver injury | 8 |

ALC: Absolute lymphocyte count; ALP: Alkaline phosphatase; ANC: Absolute neutrophil count; CAC: COVID-associated coagulopathy; COVID-19: Coronavirus disease 2019; D-Bil: Direct bilirubin; DDIM: D-dimer; HGB: Hemoglobin; ICU: Intensive care unit; INR: International normalized ratio; LFT: Liver function test; NOS: Newcastle-Ottawa Scale; PLT: Platelet count; PT: Prothrombin time; PTT: Partial thromboplastin time; WBC: White blood cell count.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**